Evidence map›Paper›PMID 42569220›Full record

ArticleFrontiers in immunology2026

A robust and scalable immunoadsorbent platform based on the high-affinity M03-IgG antibody for targeted IL-6 Removal in cytokine storm.

Yaxi Yang, Lei Wan, Youjia Qin, Jiangtao Guo, Yong Wang, Kangkang Ji, Sheng Hu, Mingqian Feng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yaxi YangCollege of Biomedicine and Health, Huazhong Agricultural University, Wuhan, Hubei, China.
Lei WanCollege of Biomedicine and Health, Huazhong Agricultural University, Wuhan, Hubei, China.
Youjia QinCollege of Biomedicine and Health, Huazhong Agricultural University, Wuhan, Hubei, China.
Jiangtao GuoCollege of Biomedicine and Health, Huazhong Agricultural University, Wuhan, Hubei, China.
Yong WangCollege of Biomedicine and Health, Huazhong Agricultural University, Wuhan, Hubei, China.
Kangkang JiCollege of Life Science and Technology, Huazhong Agricultural University, Wuhan, Hubei, China.
Sheng HuDepartment of Respiratory and Critical Care Medicine, Binhai County People's Hospital, Binhai Clinical College, Yangzhou University Medical College, Yancheng, Jiangsu, China.
Mingqian FengCollege of Biomedicine and Health, Huazhong Agricultural University, Wuhan, Hubei, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The therapeutic removal of interleukin-6 (IL-6) via blood perfusion has demonstrated clinical efficacy in the management of autoimmune diseases and sepsis. However, efficient clearance is hindered by the complexity of blood, which contains over 3,000 plasma proteins, and by the low physiological abundance of IL-6, which ranges from picograms to nanograms per milliliter even during cytokine storms. Existing adsorbents are limited by their specificity, binding capacity, and cost-effectiveness. To address these challenges, we developed an IgG-based immunoadsorbent utilizing M03-IgG, a high-affinity anti-IL-6 antibody with an EC

Indexed as

Antibodies, MonoclonalCytokine Release SyndromeImmunoglobulin GInterleukin-6AdsorptionAnimalsAntibody AffinityHumansAntibodies, MonoclonalIL6 protein, humanImmunoglobulin GInterleukin-6cytokine removalhypercytokinemiail-6immunoadsorptioninflammation

Identifiers

PMID42569220
PMCPMC13449301

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.